CD8A and breast neoplasm: These results were consistent with those of published studies, which revealed that phosphatidylinositol 3-kinase α inhibitor could promote fatty acid metabolism to activate CD8+T cells, and a combination of the inhibitor and FASN inhibitor could enhance immunity to decrease breast tumor growth [44].